HC Wainwright Reiterates “Buy” Rating for Actinium Pharmaceuticals (NYSE:ATNM)

Actinium Pharmaceuticals (NYSE:ATNM)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued on Friday,Benzinga reports. They presently have a $4.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 171.19% from the stock’s previous close.

Several other research firms have also recently weighed in on ATNM. StockNews.com cut Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday. B. Riley lowered shares of Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $16.00 to $2.00 in a report on Wednesday, August 7th. Finally, Maxim Group dropped their price target on shares of Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $11.40.

Actinium Pharmaceuticals Stock Performance

NYSE ATNM traded down $0.18 during trading on Friday, hitting $1.48. 379,311 shares of the company’s stock were exchanged, compared to its average volume of 445,123. The stock has a market capitalization of $46.01 million, a P/E ratio of -0.98 and a beta of 0.14. Actinium Pharmaceuticals has a fifty-two week low of $1.33 and a fifty-two week high of $10.24. The firm’s 50 day moving average price is $1.80.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company bought a new position in shares of Actinium Pharmaceuticals in the second quarter valued at $92,000. Renaissance Technologies LLC purchased a new position in shares of Actinium Pharmaceuticals in the 2nd quarter worth approximately $142,000. Interchange Capital Partners LLC purchased a new position in shares of Actinium Pharmaceuticals in the 3rd quarter worth about $37,000. Rhumbline Advisers increased its stake in shares of Actinium Pharmaceuticals by 23.4% during the 2nd quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after purchasing an additional 7,525 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in Actinium Pharmaceuticals in the second quarter worth $356,000. Institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).